دورية أكاديمية
[THE USE OF BORTEZOMIB FOR THE TREATMENT OF CHRONIC ANTIBODY MEDIATED REJECTION AFTER KIDNEY TRANSPLANTATION].
| العنوان: | [THE USE OF BORTEZOMIB FOR THE TREATMENT OF CHRONIC ANTIBODY MEDIATED REJECTION AFTER KIDNEY TRANSPLANTATION]. |
|---|---|
| المؤلفون: | Tasaki M; Department of Urology, Graduate School of Medical and Dental Sciences, Niigata University., Saito K; Department of Urology, Graduate School of Medical and Dental Sciences, Niigata University., Nakagawa Y; Department of Urology, Graduate School of Medical and Dental Sciences, Niigata University., Nobushita T; Department of Urology, Graduate School of Medical and Dental Sciences, Niigata University., Anraku T; Department of Urology, Graduate School of Medical and Dental Sciences, Niigata University., Kuroki H; Department of Urology, Graduate School of Medical and Dental Sciences, Niigata University., Imai N; Department of Clinical Nephrology and Rheumatology, Graduate School of Medical and Dental Sciences, Niigata University., Ito Y; Department of Clinical Nephrology and Rheumatology, Graduate School of Medical and Dental Sciences, Niigata University., Tomita Y; Department of Urology, Graduate School of Medical and Dental Sciences, Niigata University. |
| المصدر: | Nihon Hinyokika Gakkai zasshi. The japanese journal of urology [Nihon Hinyokika Gakkai Zasshi] 2018; Vol. 109 (2), pp. 68-73. |
| نوع المنشور: | Journal Article |
| اللغة: | Japanese |
| بيانات الدورية: | Publisher: Japanese Urological Association Country of Publication: Japan NLM ID: 2984841R Publication Model: Print Cited Medium: Internet ISSN: 1884-7110 (Electronic) Linking ISSN: 00215287 NLM ISO Abbreviation: Nihon Hinyokika Gakkai Zasshi Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Tokyo : Japanese Urological Association |
| مواضيع طبية MeSH: | Antibodies* , Kidney Transplantation*, Bortezomib/*administration & dosage , Graft Rejection/*immunology , Graft Rejection/*therapy , HLA Antigens/*immunology, Adolescent ; Adult ; Bortezomib/therapeutic use ; Child ; Chronic Disease ; Female ; Graft Rejection/drug therapy ; Humans ; Infusions, Intravenous ; Male ; Middle Aged ; Treatment Failure ; Young Adult |
| مستخلص: | (Backgrounds) The efficacy of bortezomib for chronic antibody mediated rejection (CAMR) after kidney transplantation is still obscure. (Materials and methods) CAMR were persisted in 5 recipients who were treated with plasma exchange, low dose of IVIG, steroid pulse therapy, and rituximab. 1.3 mg/m 2 of bortezomib was administered on days 1, 4, 8, 11. Serum creatinine (sCr) levels, anti-HLA antibodies, and histology were analyzed. (Results) Stable sCr levels were obtained in 3 out of 5 recipients. No one lost renal graft function during follow-up periods. Anti-HLA class I antibodies were significantly decreased after bortezomib treatment, however anti-HLA class II antibodies were not changed. Histology showed no improvement at 6 months after bortezomib administration. Two recipients whose sCr levels increased during follow-up had already had interstitial fibrosis and tubular atrophy (IF/TA) in histology before bortezomib treatment. (Conclusions) The use of bortezomib after IF/TA could be detected in histology may not contribute to stabilize renal graft function in CAMR. |
| فهرسة مساهمة: | Keywords: Bortezomib; Chronic antibody mediated rejection; Kidney transplantation |
| المشرفين على المادة: | 0 (Antibodies) 0 (HLA Antigens) 69G8BD63PP (Bortezomib) |
| تواريخ الأحداث: | Date Created: 20190423 Date Completed: 20190517 Latest Revision: 20190517 |
| رمز التحديث: | 20240628 |
| DOI: | 10.5980/jpnjurol.109.68 |
| PMID: | 31006744 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1884-7110 |
|---|---|
| DOI: | 10.5980/jpnjurol.109.68 |